Retrospective Study Evaluating ABRYSVO Vaccine Effectiveness Against Severe Lower Respiratory Tract Infection in Older Adults
RSV is a major cause of respiratory infection in both infants and older adults, and clinical manifestations can be severe. This study will evaluate the vaccine effectiveness of Pfizer’s ABRYSVO vaccine against RSV-related lower respiratory tract infection requiring hospitalization among Kaiser Permanente Southern California members ages 60 and older who are eligible for vaccination per current ACIP recommendations.